Cancer News
OncoLink Cancer News - HealthDay


Drugs Effective in Treating Advanced Prostate Cancer

-- A. Agrawal, PhD

Monday, April 13, 2009

MONDAY, April 13 (HealthDay News) -- Two compounds are effective in treating advanced prostate cancer resistant to first-line treatments, according to research published online April 9 in Science.

Chris Tran, from Memorial Sloan-Kettering Cancer Center in New York City, and colleagues screened for non-steroidal anti-androgens that bound to androgen receptors with high sensitivity and specificity, particularly in cells expressing high levels of androgen receptor, a hallmark of castration-resistant prostate cancer.

The researchers identified the diarylthiohydantoins RD162 and MDV3100, which had a higher affinity for androgen receptors than the clinically used anti-androgen bicalutamide and blocked the downstream effects of the receptor. In mouse models of castration-resistant prostate cancer, both compounds were able to induce tumor regression when given orally. Of 30 men with castration-resistant prostate cancer who had failed first-line anti-androgens, 43 percent of those treated with MDV3100 had declines of more than 50 percent in the levels of prostate-specific antigen, the authors report.

"These compounds thus appear to be promising candidates for treatment of advanced prostate cancer," Tran and colleagues conclude.

Abstract
Full Text (subscription or payment may be required)

Specialties Cardiology
Diabetes & Endocrinology
Internal Medicine
Family Practice

Copyright © 2009 ScoutNews, LLC. All rights reserved.


I Wish You Knew

Making treatment decisions is difficult and you can ask for help

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More